Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 10
Submit an article Journal homepage
923
Views
23
CrossRef citations to date
0
Altmetric
Original Article

Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

Kaj Stenlöf Clinical Trial Center, Sahlgrenska University Hospital, Gothenburg, SwedenCorrespondence[email protected]
,
Itamar Raz Diabetes Unit, Hadassah University Hospital, Jerusalem, Israel
,
Joel Neutel Orange County Research Center, Tustin, CA, USA
,
Shoba Ravichandran Bristol-Myers Squibb, Princeton, NJ, USA
,
Niklas Berglind Bristol-Myers Squibb, Princeton, NJ, USA
&
Roland Chen Bristol-Myers Squibb, Princeton, NJ, USA
Pages 2355-2363 | Accepted 23 Jul 2010, Published online: 31 Aug 2010

Citations (23)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Stephen L. Aronoff. (2017) Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes. Postgraduate Medicine 129:2, pages 231-241.
Read now
Peter P Toth. (2015) Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease. Vascular Health and Risk Management 11, pages 9-23.
Read now
Keith C. Ferdinand & Samar A. Nasser. (2015) Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus. Current Medical Research and Opinion 31:5, pages 913-923.
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Michel P. Hermans, Tuncay Delibasi, Ian Farmer, Leif Lohm, Pierre Maheux, PierMarco Piatti, Elmas Malvolti, Silke Jörgens & Bernard Charbonnel. (2012) Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Current Medical Research and Opinion 28:10, pages 1635-1645.
Read now
Shamsa Ali & Vivian Fonseca. (2012) Overview of metformin: special focus on metformin extended release. Expert Opinion on Pharmacotherapy 13:12, pages 1797-1805.
Read now
Sherwyn L. Schwartz. (2012) Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies. Annals of Medicine 44:2, pages 157-169.
Read now
André J Scheen. (2012) Saxagliptin plus metformin combination therapy. Expert Review of Endocrinology & Metabolism 7:2, pages 151-164.
Read now

Articles from other publishers (15)

Islam Y. Elgendy, Ahmed N. Mahmoud, Amr F. Barakat, Akram Y. Elgendy, Marwan Saad, Ahmed Abuzaid, Siddarth A. Wayangankar & Anthony A. Bavry. (2016) Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. American Journal of Cardiovascular Drugs 17:2, pages 143-155.
Crossref
Alexander Kuhn, Jean Park, Adline Ghazi & Vanita R. Aroda. (2017) Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current Cardiology Reports 19:3.
Crossref
William S. Denney, Douglas S. Denham, Michael R. Riggs & Neeta B. Amin. (2016) Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study. Clinical Pharmacology in Drug Development 5:6, pages 517-527.
Crossref
Lawrence Blonde, Zinnia T. San Juan & Peggy Bolton. (2014) Fixed-Dose Combination Therapy in Type 2 Diabetes Mellitus. Endocrine Practice 20:12, pages 1322-1332.
Crossref
Judith L White, Patricia Buchanan, Jia Li & Robert Frederich. (2014) A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. BMC Endocrine Disorders 14:1.
Crossref
Brian Bryzinski, Elsie Allen, William Cook & Boaz Hirshberg. (2014) Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy. Journal of Diabetes and its Complications 28:6, pages 887-893.
Crossref
Anders Gummesson, Haiyan Li, Michael Gillen, John Xu, Mohammad Niazi & Boaz Hirshberg. (2014) Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects. Clinical Drug Investigation 34:11, pages 763-772.
Crossref
Boaz Hirshberg, Artist Parker, Helen Edelberg, Mark Donovan & Nayyar Iqbal. (2014) Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews 30:7, pages 556-569.
Crossref
Antonio R. Chacra. (2014) Evolving Metformin Treatment Strategies in Type-2 Diabetes. American Journal of Therapeutics 21:3, pages 198-210.
Crossref
Nayyar Iqbal, Artist Parker, Robert Frederich, Mark Donovan & Boaz Hirshberg. (2014) Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovascular Diabetology 13:1, pages 33.
Crossref
Joel M. Neutel, Cathy Zhao & Chetan S. Karyekar. (2013) Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures. Diabetes Therapy 4:2, pages 269-283.
Crossref
Haiyan Li, Li Yang, Conrad K.P. Tou, Chirag G. Patel & June Zhao. (2012) Pharmacokinetic Study of Saxagliptin in Healthy Chinese Subjects. Clinical Drug Investigation 32:7, pages 465-473.
Crossref
V. Fonseca, T. Zhu, C. Karyekar & B. Hirshberg. (2012) Adding saxagliptin to extended‐release metformin vs. uptitrating metformin dosage. Diabetes, Obesity and Metabolism 14:4, pages 365-371.
Crossref
Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Ph. Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Deborah L. Price, Roland Chen, Jacob Udell & Itamar Raz. (2011) The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study. American Heart Journal 162:5, pages 818-825.e6.
Crossref
Deanna S. Kania, Jasmine D. Gonzalvo & Zachary A. Weber. (2011) Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics 33:8, pages 1005-1022.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.